Turning the body's own repair signal into a pill for the muscle loss that comes with age.
In a lab off Towne Centre Drive, roughly a dozen people are betting that aging muscle can be told to repair itself.
Epirium Bio is a clinical-stage biopharmaceutical company. That phrase does a lot of quiet work. It means the science has left the bench and entered human beings. It means there is a lead drug - MF-300 - that has been swallowed by healthy volunteers, measured, and judged safe enough to move forward. And it means the company is now standing at the edge of the trial that decides everything: a Phase 2b in sarcopenia, the age-related loss of muscle strength.
For a company founded in 2008, this is not an overnight story. It is closer to the opposite. Epirium spent more than a decade in the unglamorous middle of drug discovery before its breakout moment. The interesting part is what it was waiting for.
Here is an uncomfortable fact. The FDA estimates that up to a third of Americans over the age of 60 are affected by sarcopenia - the steady, often invisible erosion of muscle strength that makes stairs harder, falls more likely, and recovery slower. It is one of the most common conditions of aging.
And there are no FDA-approved therapies for it. None. The standard advice is exercise and protein, which is excellent advice and also not a drug. For a problem this widespread, the absence of a pill is conspicuous.
That gap is the tension Epirium exists inside. A condition affecting tens of millions of people, costly to the healthcare system, and treatment-free. Most companies look at "no approved therapy" and see risk. Epirium looked at it and saw the reason to exist.
Epirium's origins trace to a group of physician-scientists - Pam Taub, Alan Maisel, Francisco Villarreal, Jonathan Taub, and Guillermo Ceballos - working on tissue bioenergetics and the machinery of repair. The bet that eventually defined the company is counterintuitive.
Most drugs add something foreign to the body. Epirium's approach is to take something away. Its lead molecule inhibits an enzyme called 15-PGDH, whose job is to break down PGE2 - a signal the body uses to resolve inflammation and drive tissue repair. Block the enzyme, and the body's own repair signal rises. No synthetic substitute. Just a foot off the brake.
In 2019 the bet got funded, and not modestly. Epirium raised an $85 million Series A co-led by Longitude Capital and ARCH Venture Partners, with Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund joining. Then, in a move that says something about how the company sees its next chapter, it brought in leadership from the operating and investing worlds: Russell Cox, formerly of Jazz Pharmaceuticals, and later Alex Casdin, a healthcare investor who took the CEO seat in 2025.
The thing about a mechanism is that it rarely respects the boundaries of a single disease. Epirium's 15-PGDH platform started with muscle, but the same biology - resolve inflammation, stimulate regeneration, reduce fibrosis - shows up in the gut, the lung, and the rare neuromuscular disorders that medicine has long struggled with.
A first-in-class, orally administered 15-PGDH enzyme inhibitor for sarcopenia. Completed a positive Phase 1 in healthy volunteers, with a Phase 2b expected in the second half of 2026.
An oral synthetic compound aimed at Becker muscular dystrophy, extending the platform from common aging into rare inherited muscle disease.
A portfolio of orally bioavailable small molecules that enhance endogenous PGE2 signaling - the foundation everything else is built on.
Earlier-stage candidates for spinal muscular atrophy, inflammatory bowel disease, and idiopathic pulmonary fibrosis - one mechanism, several frontiers.
Four programs, one underlying idea. Biology, for once, sharing nicely.
A group of physician-scientists begins work on tissue bioenergetics and the biology of repair in San Diego.
Co-led by Longitude Capital and ARCH Venture Partners to advance the platform from discovery into the clinic.
The Investigational New Drug application is cleared; Alex Casdin is named incoming CEO and Russell Cox becomes Executive Chairman.
MF-300 is generally well tolerated across all doses in healthy volunteers, with dose-related pharmacodynamic responses observed.
The FDA supports advancing MF-300 to a Phase 2b trial in sarcopenia; new clinical and translational data slated for conference presentation.
The trial that will test whether the mechanism holds in the patients who need it most.
Skeptics are right to ask why this matters now. The answer is partly clinical - a clean Phase 1, a supportive FDA - and partly arithmetic. The size of the untreated population is the argument.
A bar chart where the most dramatic number is the empty one: zero approved drugs.
Strip away the enzyme names and the trial phases, and Epirium's mission is almost philosophical. The body already knows how to repair tissue, resolve inflammation, and rebuild muscle. It does it constantly, until age and disease wear the machinery down. Epirium isn't trying to invent repair. It's trying to remove the obstacles to it.
That framing matters for who Epirium serves. Today, the answer is clinical trial participants and the investigators running the studies. Tomorrow, if the science holds, it is the tens of millions of people for whom losing muscle has been treated as an inevitability rather than a condition.
Return to where this started: a small team, a single lead drug, and a very large question. What's changed is that the question now has data behind it. A drug that exists. A trial that's funded. A regulator that nodded.
None of that guarantees the Phase 2b works - clinical biology has humbled better-resourced companies. But the shape of the bet is clear, and it's a good one. If MF-300 does for patients what it did for the underlying biology, a condition that medicine treated as a fact of aging becomes something you can take a pill for. That dozen people in San Diego would have changed what getting older feels like.
For now, they wait on the trial. The rest of us get older. Epirium is betting those two facts don't have to stay connected.
No official Epirium Bio YouTube channel, interview, or product-demo video was found at the time of writing. Check the press releases page above for the latest media.